現在価格
目標株価
アナリスト評価
6 評価: 買い
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company dedicated to addressing critical unmet medical needs in neurodegenerative diseases with its proprietary nerve regeneration technology platform. The compa...|
e.g. Promoter holding
Loading chart...
アナリストによるEPSおよび売上高の予想コンセンサス。
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 |
|---|---|---|---|---|---|
| $-0.06 | $-0.07 | $-0.10 | $-0.49 | $-0.34 | |
| 0 | 0 | 0 | 0 | 0 | |
| — | -1.5% | +2.8% | +2.0% | +0.8% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LLENZ Thera... | LENZ | $129.77M | — | 0.68 | — | -1,211.00% | -72.70% | -72.90% |
| 2. | AAnixa Bios... | ANIX | $91.08M | — | 6.29 | — | — | -73.20% | — |
| 3. | CCaribou Bi... | CRBU | $39.10M | — | 0.51 | — | -1,141.00% | -93.80% | -26.90% |
| 4. | UUnicycive... | UNCY | $97.25M | — | 1.86 | — | — | -101.10% | — |
| 5. | ZZura Bio | ZURA | $119.44M | — | 0.67 | — | — | -63.20% | — |
連結数値(百万円)/単体表示可
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.03 | 0.01 | 0.01 |
Gross Profit | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.03 | -0.01 | -0.01 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 5.33 | 4.72 | 4.18 | 4.74 | 4.42 | 11.73 | 7.64 | 12.51 | |
EBIT | -5.34 | -4.73 | -4.19 | -4.75 | -4.43 | -11.7 | -7.66 | -12.52 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | 0 | -1.25 | 1.45 | -1.94 | 1.45 | -20 | 5.95 | 0 |
PBT | -3.91 | -5.98 | -2.74 | -6.69 | -2.98 | -31.7 | -1.7 | -29.99 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -3.91 | -5.98 | -2.74 | -6.69 | -2.98 | -31.7 | -1.7 | -29.99 |
NPM % | - | - | - | - | - | - | - | - |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0.01 | 0.03 | 0.03 | 0.03 | 0.08 | 0.11 | 0.06 | 0 |
Gross Profit | 0 | -0.01 | -0.03 | -0.03 | -0.03 | -0.08 | -0.11 | -0.06 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - | - |
| 0.01 | 0.98 | 7.58 | 8.76 | 10.09 | 16.9 | 13.3 | 17.27 | 25.08 | |
EBIT | -0.01 | -0.99 | -7.61 | -8.79 | -10.13 | -16.99 | -13.41 | -17.33 | -25.08 |
OPM % | - | - | - | - | - | - | - | - | - |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 | 1.7 | -3.47 | 0.64 | -19.04 |
PBT | -0.01 | -0.99 | -7.53 | -8.78 | -10.06 | -15.29 | -16.89 | -16.68 | -44.12 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - | - |
Net Income | -0.01 | -0.99 | -7.53 | -8.78 | -10.06 | -15.29 | -16.89 | -16.68 | -44.12 |
NPM % | - | - | - | - | - | - | - | - | - |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1.81 | 3.17 | 4.39 | 13.38 | 16.56 | 8.8 | 12 | 22.07 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.08 | 0.01 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0.06 | 1.66 | 0.47 | 0.39 | 0.51 | 0.65 | 1.15 | 0.73 | |
| 0 | 0.4 | 0.39 | 0.37 | 0.38 | 0.54 | 0.54 | 0.32 | 0.4 | |
Total Assets | 0 | 2.27 | 5.22 | 5.24 | 14.15 | 17.61 | 9.99 | 13.54 | 23.21 |
| 0 | 2.82 | 11.79 | 18.01 | 33.52 | 42.35 | 44.46 | 56.36 | 103 | |
| 0 | -0.98 | -7.29 | -13.36 | -20.23 | -32.42 | -45.98 | -54.57 | -99.52 | |
| 0 | 0 | 0 | 0 | 0 | 0.21 | 0.15 | 0.07 | 0.01 | |
| 0 | 0.33 | 0.71 | 0.59 | 0.85 | 9.48 | 14.67 | 11.68 | 19.72 | |
| 0 | 0.1 | 0 | 0 | 0 | -2 | -3.32 | 0 | 0 | |
Total Liabilities | 0 | 2.27 | 5.22 | 5.24 | 14.15 | 17.61 | 9.99 | 13.54 | 23.21 |
連結数値(百万円)/単体表示可
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| -0.76 | -6.24 | -4.95 | -6.54 | -13.12 | -8.52 | -11.7 | -19.5 | |
| -0.09 | 0 | -0 | -0.04 | -0.02 | -0.1 | 0.04 | 0.1 | |
| 2.63 | 7.59 | 6.16 | 15.51 | 16.7 | 0.58 | 15.77 | 23.76 | |
Net CFNet Cash Flow | 1.78 | 1.35 | 1.21 | 8.93 | 3.57 | -8.05 | 4.11 | 4.37 |
FCFFree Cash Flow | -0.76 | -6.24 | -4.95 | -6.54 | -13.13 | -8.53 | -11.7 | -19.5 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | -237.4% | -191.9% | -112.1% | -131.6% | -401.4% | -12149.2% | -1675.1% | |
| - | - | - | - | - | 0.02 | -0.10 | 0.04 | 0.00 | |
| - | 5.68 | 6.77 | 8.21 | 16.16 | 2.27 | 0.83 | 1.12 | 1.16 | |
| - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | - | 0.77 | 0.83 | 0.56 | 0.65 | 0.86 | 0.50 | 0.70 | 0.44 |
Payout Ratio | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | |
| - | 3.00 | 3.00 | 3.00 | 4.00 | 2.00 | 2.00 | 4.00 | 3.00 | |
| - | - | - | - | - | - | - | - | - | |
| - | 0.00 | 0.00 | 0.00 | 0.00 | 50.00 | - | 50.00 | 50.00 | |
| - | - | - | - | - | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
NANOGEN INCの株主構成(SEC提出書類より)
この企業のSEC保有報告はまだありません。
NANOGEN INCのSEC提出書類と決算説明会の議事録
この企業のSEC提出書類はまだありません。
What recent news says about NANOGEN INC, scored for sentiment.